Evidence Based Research on

AUTOLOGOUS STEM CELL THERAPY

Autologous Stem Cell Therapy facts:

The word Autologous means derived from recipient receiving graft.


A stem cell is an unspecified cell that can both self-renew (reproduce itself) and differentiate into mature cells/tissues such as collagen, skin, cartilage, heart, lung, and pancreas.


Stem cells can be collected from peripheral blood or bone marrow.


Peripheral Blood stem cells are easier and less painful to collect than Bone Marrow stem cells.


Peripheral Blood collection also yields more stem cells than bone marrow collection.


 

Intravenous administration of mesenchymal stem cells derived from bone marrow after contusive spinal cord injury improves functional outcome.

 

Osaka M, Honmou O, Murakami T, Nonaka T, Houkin K, Hamada H, Kocsis JD.
Brain Res. 2010 Jul 9;1343:226-35. Epub 2010 May 12.

 

Source

 

Department of Neurosurgery, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan. Abstract

 

Abstract

 

Transplantation of mesenchymal stem cells (MSCs) derived from bone marrow has been shown to improve functional outcome in spinal cord injury (SCI). Systemic delivery of MSCs results in therapeutic benefits in a number of experimental central nervous system disorders. In the present study we intravenously administered rat MSCs derived from bone marrow at various time points after induction of a severe contusive SCI in rats to study their therapeutic effects. Locomotor recovery improvement was greater in the MSC-treated groups than in sham controls, with greatest improvement in the earlier post-contusion infusion times. The availability of autologous MSCs in large number and the potential for systemically delivering cells to target lesion areas without neurosurgical intervention suggests the potential utility of intravenous cell delivery as a prospective therapeutic approach in acute and subacute Spinal Cord Injury.

 

Copyright (c) 2010 Elsevier B.V. All rights reserved.

(Some of these procedures are in the experimental stage and are not the present standard of care, but all of these procedures are established under Federal Rules 21 CFR 1271.15 (b) and the California B&P Code section 2053.5.). This Institute does NOT use collagenase.